Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

PURPOSE: SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133–tositumomab radioimmunotherapy) for previously untreated pati...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Oncol
Main Authors: Shadman, Mazyar, Li, Hongli, Rimsza, Lisa, Leonard, John P., Kaminski, Mark S., Braziel, Rita M., Spier, Catherine M., Gopal, Ajay K., Maloney, David G., Cheson, Bruce D., Dakhil, Shaker, LeBlanc, Michael, Smith, Sonali M., Fisher, Richard I., Friedberg, Jonathan W., Press, Oliver W.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2018
נושאים:
ORIGINAL REPORTS
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553811/
https://ncbi.nlm.nih.gov/pubmed/29356608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.74.5083
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים